Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 in mCRPC With Bone Marrow Involvement and Cytopenia
NCT07025512Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Aug 2025; status: withdrawn.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07025512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025512.